<p>Opus Genetics, Inc.（纳斯达克：IRD - 获取免费报告）首席运营官 Joseph Schachle 于 4 月 23 日星期四出售了该公司 4,697 股股票。股票的平均售价为 5.22 美元，总价值为 24,518.34 美元。出售完成后，首席运营官直接持有该公司 296,084 股股票，估值约为 1,545,558.48 美元。此次交易使其持股比例减少了 1.56%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。此次出售是为了覆盖与股权奖励归属相关的税收扣缴义务。</p>
<p>获取 <strong>Opus Genetics</strong> 的提醒：</p>
<h2>Opus Genetics 股票下跌 2.1%</h2>
<ul>
<li>未来十年可能飙升的 5 只太空股票</li>
</ul>
<p>在周一的交易中，纳斯达克 IRD 的股票下跌了 0.11 美元，达到 5.12 美元。该公司的交易量为 736,774 股，而其平均交易量为 885,269 股。Opus Genetics, Inc.的 12 个月低点为 0.81 美元，12 个月高点为 5.81 美元。该股票的市值为 3.6557 亿美元，市盈率为-6.24，贝塔值为 0.52。该公司的 50 日移动平均线为 4.67 美元，200 日移动平均线为 3.07 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家研究公司最近对 IRD 发表了评论。Oppenheimer 在 3 月 16 日的研究报告中开始覆盖 Opus Genetics。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 10.00 美元的目标价。Weiss Ratings 在 4 月 21 日的研究报告中重新发布了对 Opus Genetics 的 “卖出（d-）” 评级。Craig Hallum 在 3 月 11 日的研究报告中对 Opus Genetics 设定了 9.00 美元的目标价，并给予该股票 “买入” 评级。Lifesci Capital 在 2 月 12 日的研究报告中将 Opus Genetics 的评级提升至 “强力买入”。最后，Wall Street Zen 在 3 月 1 日的报告中将 Opus Genetics 的评级从 “卖出” 提升至 “持有”。一位投资分析师对该股票给予了强力买入评级，九位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 10.11 美元。</p>
<ul>
<li>信号提升：推动行业增长的 2 只关键卫星股票</li>
</ul>
<p><strong>获取我们关于 IRD 的最新研究报告</strong></p>
<h2>机构资金流入和流出</h2>
<p>对该公司的对冲基金和其他机构投资者最近调整了他们的持股。Occudo Quantitative Strategies LP 在第四季度购买了价值 25,000 美元的 Opus Genetics 新头寸。Comerica Bank 在第一季度购买了价值 29,000 美元的 Opus Genetics 新头寸。Virtu Financial LLC 在第四季度购买了价值 34,000 美元的 Opus Genetics 新头寸。Raymond James Financial Inc.在第三季度将其在 Opus Genetics 的持股提高了 95.6%。Raymond James Financial Inc.现在拥有 22,508 股该公司的股票，价值 37,000 美元，此前在上个季度购买了额外的 11,000 股。最后，Johnson Investment Counsel Inc.在第四季度购买了价值 40,000 美元的 Opus Genetics 新头寸。14.97% 的股票由机构投资者持有。</p>
<h2>关于 Opus Genetics</h2>
<p>（获取免费报告）</p>
<ul>
<li>这 3 只股票能否因三位数的收益增长而飙升？</li>
</ul>
<p>Opus Genetics Inc 是一家临床阶段的眼科生物制药公司，专注于开发和商业化治疗屈光和视网膜眼病患者未满足需求的疗法。Opus Genetics Inc，前身为 Ocuphire Pharma Inc，总部位于密歇根州法明顿山。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Opus Genetics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJE"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Opus Genetics 吗？</h2>
<p>在你考虑 Opus Genetics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Opus Genetics 并不在名单上。</p>
<p>虽然 Opus Genetics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

<p>Opus Genetics 首席运营官 Joseph Schachle 于 4 月 23 日以平均价格 5.22 美元出售了 4,697 股公司股票，交易总额为 24,518.34 美元。出售后，他持有 296,084 股，估值约为 155 万美元，反映出其持股比例下降了 1.56%。此次出售是为了支付与股权奖励相关的税务义务。该股票目前交易价格为 5.12 美元，下跌 2.1%，市值为 3.6557 亿美元。分析师的评级意见不一，普遍目标价为 10.11 美元</p>

<p>Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) COO Joseph Schachle sold 4,697 shares of the company's stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $5.22, for a total value of $24,518.34. Following the completion of the sale, the chief operating officer directly owned 296,084 shares in the company, valued at approximately $1,545,558.48. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.</p>
<div class="lb-trans"><p>Opus Genetics, Inc.（纳斯达克：IRD - 获取免费报告）首席运营官 Joseph Schachle 于 4 月 23 日星期四出售了该公司 4,697 股股票。股票的平均售价为 5.22 美元，总价值为 24,518.34 美元。出售完成后，首席运营官直接持有该公司 296,084 股股票，估值约为 1,545,558.48 美元。此次交易使其持股比例减少了 1.56%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。此次出售是为了覆盖与股权奖励归属相关的税收扣缴义务。</p>
</div><p>Get <strong>Opus Genetics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Opus Genetics</strong> 的提醒：</p>
</div><h2>Opus Genetics Stock Down 2.1%</h2>
<div class="lb-trans"><h2>Opus Genetics 股票下跌 2.1%</h2>
</div><ul>
<li>5 Space Stocks That Could Soar in the Next Decade</li>
</ul>
<div class="lb-trans"><ul>
<li>未来十年可能飙升的 5 只太空股票</li>
</ul>
</div><p>Shares of NASDAQ IRD traded down $0.11 during trading on Monday, reaching $5.12. The company had a trading volume of 736,774 shares, compared to its average volume of 885,269. Opus Genetics, Inc. has a 12-month low of $0.81 and a 12-month high of $5.81. The stock has a market cap of $365.57 million, a PE ratio of -6.24 and a beta of 0.52. The business's 50-day moving average is $4.67 and its 200 day moving average is $3.07.</p>
<div class="lb-trans"><p>在周一的交易中，纳斯达克 IRD 的股票下跌了 0.11 美元，达到 5.12 美元。该公司的交易量为 736,774 股，而其平均交易量为 885,269 股。Opus Genetics, Inc.的 12 个月低点为 0.81 美元，12 个月高点为 5.81 美元。该股票的市值为 3.6557 亿美元，市盈率为-6.24，贝塔值为 0.52。该公司的 50 日移动平均线为 4.67 美元，200 日移动平均线为 3.07 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research firms have recently commented on IRD. Oppenheimer began coverage on Opus Genetics in a research note on Monday, March 16th. They issued an &#34;outperform&#34; rating and a $10.00 target price on the stock. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Opus Genetics in a research note on Tuesday, April 21st. Craig Hallum set a $9.00 target price on Opus Genetics and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, March 11th. Lifesci Capital raised Opus Genetics to a &#34;strong-buy&#34; rating in a research note on Thursday, February 12th. Finally, Wall Street Zen raised Opus Genetics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, March 1st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $10.11.</p>
<div class="lb-trans"><p>多家研究公司最近对 IRD 发表了评论。Oppenheimer 在 3 月 16 日的研究报告中开始覆盖 Opus Genetics。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 10.00 美元的目标价。Weiss Ratings 在 4 月 21 日的研究报告中重新发布了对 Opus Genetics 的 “卖出（d-）” 评级。Craig Hallum 在 3 月 11 日的研究报告中对 Opus Genetics 设定了 9.00 美元的目标价，并给予该股票 “买入” 评级。Lifesci Capital 在 2 月 12 日的研究报告中将 Opus Genetics 的评级提升至 “强力买入”。最后，Wall Street Zen 在 3 月 1 日的报告中将 Opus Genetics 的评级从 “卖出” 提升至 “持有”。一位投资分析师对该股票给予了强力买入评级，九位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 10.11 美元。</p>
</div><ul>
<li>Signal Boost: 2 Key Satellite Stocks Driving Industry Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>信号提升：推动行业增长的 2 只关键卫星股票</li>
</ul>
</div><p><strong>Get Our Latest Research Report on IRD</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 IRD 的最新研究报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the business. Occudo Quantitative Strategies LP bought a new position in shares of Opus Genetics during the fourth quarter valued at $25,000. Comerica Bank bought a new position in shares of Opus Genetics during the first quarter valued at $29,000. Virtu Financial LLC bought a new position in shares of Opus Genetics during the fourth quarter valued at $34,000. Raymond James Financial Inc. lifted its holdings in shares of Opus Genetics by 95.6% during the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company's stock valued at $37,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Johnson Investment Counsel Inc. bought a new position in shares of Opus Genetics during the fourth quarter valued at $40,000. 14.97% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>对该公司的对冲基金和其他机构投资者最近调整了他们的持股。Occudo Quantitative Strategies LP 在第四季度购买了价值 25,000 美元的 Opus Genetics 新头寸。Comerica Bank 在第一季度购买了价值 29,000 美元的 Opus Genetics 新头寸。Virtu Financial LLC 在第四季度购买了价值 34,000 美元的 Opus Genetics 新头寸。Raymond James Financial Inc.在第三季度将其在 Opus Genetics 的持股提高了 95.6%。Raymond James Financial Inc.现在拥有 22,508 股该公司的股票，价值 37,000 美元，此前在上个季度购买了额外的 11,000 股。最后，Johnson Investment Counsel Inc.在第四季度购买了价值 40,000 美元的 Opus Genetics 新头寸。14.97% 的股票由机构投资者持有。</p>
</div><h2>About Opus Genetics</h2>
<div class="lb-trans"><h2>关于 Opus Genetics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>Can These 3 Stocks Soar On Triple-Digit Earnings Increases?</li>
</ul>
<div class="lb-trans"><ul>
<li>这 3 只股票能否因三位数的收益增长而飙升？</li>
</ul>
</div><p>Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.</p>
<div class="lb-trans"><p>Opus Genetics Inc 是一家临床阶段的眼科生物制药公司，专注于开发和商业化治疗屈光和视网膜眼病患者未满足需求的疗法。Opus Genetics Inc，前身为 Ocuphire Pharma Inc，总部位于密歇根州法明顿山。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Opus Genetics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Opus Genetics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJE" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=IRD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Opus Genetics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Opus Genetics 吗？</h2>
</div><p>Before you consider Opus Genetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Opus Genetics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opus Genetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Opus Genetics 并不在名单上。</p>
</div><p>While Opus Genetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Opus Genetics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Opus Genetics (NASDAQ:IRD) COO Sells $24,518.34 in Stock

Market Beat

Opus Genetics

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做空 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

动态生物技术与基因组 ETF - Invesco

Opus Genetics（NASDAQ 代码：IRD）的首席运营官出售了价值 24,518.34 美元的股票